Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and <i>Pneumocystis</i> Pneumonia
Lynn Miesel, Melanie T. Cushion, Alan Ashbaugh, Santiago Rodríguez López, Voon Ong
Abstract
Antifungal prophylaxis is recommended to prevent invasive fungal disease caused by Candida spp., Aspergillus spp., and Pneumocystis jirovecii in patients at risk for opportunistic infections, such as allogeneic blood or marrow transplant recipients, patients with hematological disease undergoing chemotherapy, or patients on immunosuppressive therapies. Current approaches to antifungal prophylaxis require multiple agents to cover these key fungi.
Topics & Concepts
AspergillosisPneumocystis jiroveciiMycosisPneumoniaOpportunistic infectionPneumocystis pneumoniaMedicineImmunologyFungal diseaseAntifungalBiologyInternal medicineHuman immunodeficiency virus (HIV)DermatologyViral diseaseAntifungal resistance and susceptibilityFungal Infections and StudiesPneumocystis jirovecii pneumonia detection and treatment